Diaz Johan, Koza Eric, Chaudhary Durgesh, Shahjouei Shima, Naved Md Mobasshir Arshed, Malik Muhammad Taimur, Li Jiang, Adibuzzaman Mohammad, Griffin Paul, Abedi Vida, Zand Ramin
Geisinger Commonwealth School of Medicine, Scranton, PA, USA.
Neurology Department, Neuroscience Institute, Geisinger Health System, Danville, PA, USA.
J Neurol Sci. 2021 May 15;424:117410. doi: 10.1016/j.jns.2021.117410. Epub 2021 Mar 20.
This study aimed to investigate the prevalence and factors associated with oral anticoagulant undertreatment of atrial fibrillation (AF) among a cohort of rural patients with stroke outcomes and examine how undertreatment may influence a patient's one-year survival after stroke.
This retrospective cohort study examined ischemic stroke patients with pre-stroke AF diagnosis from September 2003 to May 2019 and divided them into proper treatment and undertreatment group. Analysis included chi-square test, variance analysis, Kruskal-Wallis test, logistic regression, Kaplan-Meier estimator, and Cox proportional-hazards model.
Out of 1062 ischemic stroke patients with a pre-stroke AF diagnosis, 1015 patients had a CHADS-VASc score ≥2, and 532 (52.4%) of those were undertreated. Median time from AF diagnosis to index stroke was significantly lower among undertreated patients (1.9 years vs. 3.6 years, p < 0.001). Other thromboembolism, excluding stroke, TIA, and myocardial infarction (OR 0.41, p < 0.001), the number of encounters per year (OR 0.90, p < 0.001), and the median time between AF diagnosis and stroke event (OR 0.86, p < 0.001) were negatively associated with undertreatment. Kaplan-Meier estimator showed no statistical difference in the one-year survival probability between groups (log-rank test, p = 0.29), while the Cox-Hazard model showed that age (HR 1.05, p < 0.001) and history of congestive heart failure (HR 1.88, p < 0.001) increased the risk of mortality.
More than half of our rural stroke patients with a pre-index AF diagnosis were not on guideline-recommended treatment. The study highlights a large care gap and an opportunity to improve AF management.
本研究旨在调查一组有卒中结局的农村房颤(AF)患者口服抗凝治疗不足的患病率及相关因素,并探讨治疗不足如何影响患者卒中后的一年生存率。
这项回顾性队列研究对2003年9月至2019年5月期间诊断为卒中前房颤的缺血性卒中患者进行了检查,并将他们分为适当治疗组和治疗不足组。分析包括卡方检验、方差分析、Kruskal-Wallis检验、逻辑回归、Kaplan-Meier估计法和Cox比例风险模型。
在1062例诊断为卒中前房颤的缺血性卒中患者中,1015例患者的CHADS-VASc评分≥2,其中532例(52.4%)治疗不足。治疗不足的患者从房颤诊断到首次卒中的中位时间显著更短(1.9年对3.6年,p<0.001)。其他血栓栓塞事件,不包括卒中、短暂性脑缺血发作和心肌梗死(比值比0.41,p<0.001)、每年就诊次数(比值比0.90,p<0.001)以及房颤诊断与卒中事件之间的中位时间(比值比0.86,p<0.001)与治疗不足呈负相关。Kaplan-Meier估计法显示两组之间的一年生存概率无统计学差异(对数秩检验,p=0.29),而Cox风险模型显示年龄(风险比1.05,p<0.001)和充血性心力衰竭病史(风险比1.88,p<0.001)会增加死亡风险。
我们研究中超过一半诊断为卒中前房颤的农村卒中患者未接受指南推荐的治疗。该研究凸显了巨大的护理差距以及改善房颤管理的机会。